更正：费姆斯特等人。交叉反应性和交叉保护对肺炎球菌疫苗开发的影响。2024年，，974。 （注：原文中两个逗号位置不太明确其确切含义，可能存在信息不完整情况）
Correction: Feemster et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. 2024, , 974.
作者信息
Feemster Kristen, Hausdorff William P, Banniettis Natalie, Platt Heather, Velentgas Priscilla, Esteves-Jaramillo Alejandra, Burton Robert L, Nahm Moon H, Buchwald Ulrike K
机构信息
Merck & Co., Inc., Rahway, NJ 07065, USA.
Center for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA.
出版信息
Vaccines (Basel). 2025 Aug 4;13(8):831. doi: 10.3390/vaccines13080831.
Abstract
The authors would like to make the following corrections to this published paper [...].
摘要
作者希望对已发表的这篇论文做出以下更正[……]。
相似文献
1
Correction: Feemster et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. 2024, , 974.更正：费姆斯特等人。交叉反应性和交叉保护对肺炎球菌疫苗开发的影响。2024年，，974。 （注：原文中两个逗号位置不太明确其确切含义，可能存在信息不完整情况）
Vaccines (Basel). 2025 Aug 4;13(8):831. doi: 10.3390/vaccines13080831.
2
Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.交叉反应性和交叉保护性对肺炎球菌疫苗研发的影响
Vaccines (Basel). 2024 Aug 28;12(9):974. doi: 10.3390/vaccines12090974.
3
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.肺炎球菌结合疫苗的免疫原性和血清效力：系统评价和网络荟萃分析。
Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079.
4
Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. 2025, 467.更正：黄等人。四价流感亚单位疫苗在6至35个月健康儿童中的安全性和免疫原性：一项随机、盲法和阳性对照的III期临床试验。2025年，467。
Vaccines (Basel). 2025 Aug 1;13(8):826. doi: 10.3390/vaccines13080826.
5
Vaccines for preventing infections in adults with solid tumours.用于预防实体瘤成年患者感染的疫苗。
Cochrane Database Syst Rev. 2025 Apr 16;4(4):CD015551. doi: 10.1002/14651858.CD015551.pub2.
6
Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease.用于预防慢性阻塞性肺疾病患者肺炎球菌感染的注射用疫苗。
Cochrane Database Syst Rev. 2010 Nov 10(11):CD001390. doi: 10.1002/14651858.CD001390.pub3.
7
Knowledge, Attitude, and Practice of Adult Pneumococcal Vaccination in India: A Prospective, Cross-sectional, Questionnaire-based Survey of Pediatricians.印度成人肺炎球菌疫苗接种的知识、态度和实践：一项针对儿科医生的前瞻性横断面问卷调查
J Assoc Physicians India. 2025 May;73(5S):15-20. doi: 10.59556/japi.73.0991.
8
Quantitative Methods for Evaluating Antibody Responses to Pneumococcal Vaccines: A Scoping Review.评估肺炎球菌疫苗抗体反应的定量方法：一项范围综述
Trop Med Infect Dis. 2025 Aug 21;10(8):236. doi: 10.3390/tropicalmed10080236.
9
Economic Evaluation of PHID-CV versus PCV10-SII Compared with no Vaccination in the Philippines.菲律宾10价肺炎球菌结合疫苗-常规免疫规划（PHID-CV）与10价肺炎球菌结合疫苗-序贯免疫接种（PCV10-SII）对比未接种疫苗的经济学评估
Infect Dis Ther. 2025 Jun 2. doi: 10.1007/s40121-025-01162-x.
10
Pneumococcal vaccination during pregnancy for preventing infant infection.孕期接种肺炎球菌疫苗以预防婴儿感染。
Cochrane Database Syst Rev. 2015 Jan 23;1(1):CD004903. doi: 10.1002/14651858.CD004903.pub4.
本文引用的文献
1
Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.交叉反应性和交叉保护性对肺炎球菌疫苗研发的影响
Vaccines (Basel). 2024 Aug 28;12(9):974. doi: 10.3390/vaccines12090974.
Zotero 插件